Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.95 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL15710835 | 1.00 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL27541061 | 0.98 | EGFR (0.91) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL29356169 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL29490398 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL5920 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL22833783 | 0.98 | EGFR (1.00) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| SCHEMBL3196932 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL4487630 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL1119374 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 | |
| Quinazoline SCHEMBL21055790 | 0.95 | EGFR (0.95) | EGFRPIK3CDPIK3CAALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105358546-B | The tetrahydro carbazole being substituted and carbazole carboxamide compounds useful as kinase inhibitor | 百时美施贵宝公司 | 2017-10-31 | — | — | CN | claimed |
| CN-110003121-A | A kind of 3,4- dihydroquinazoline derivatives and preparation method thereof, application | 郑州大学 | 2019-07-12 | — | — | CN | disclosed |
| CN-109810066-A | A kind of synthetic method of the ambroxol hydrochloride in relation to substance | 合肥学院 | 2019-05-28 | — | — | CN | disclosed |
| CN-109789221-A | Incremental dose discovery in controlled release PTH compounds | 阿森迪斯药物骨疾病股份有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109651375-A | A kind of tetrahydro quinazoline derivative and its synthetic method and application | 上海应用技术大学 | 2019-04-19 | — | — | CN | disclosed |
| CN-108727343-A | Quinazolinones PARP-1/2 inhibitor containing 3- amino nafoxidines and preparation method thereof, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2018-11-02 | — | — | CN | disclosed |
| CN-105358546-B | The tetrahydro carbazole being substituted and carbazole carboxamide compounds useful as kinase inhibitor | 百时美施贵宝公司 | 2017-10-31 | — | — | CN | disclosed |
| CN-106986857-A | Trk inhibiting compounds | 小野药品工业株式会社 | 2017-07-28 | — | — | CN | disclosed |
| CN-106928197-A | Trk inhibiting compounds | 小野药品工业株式会社 | 2017-07-07 | — | — | CN | disclosed |
| CN-106749045-A | A kind of new D amino acid oxidase inhibitors and its preparation method and application | 上海交通大学 | 2017-05-31 | — | — | CN | disclosed |
| CN-101348484-A | Pyrido[3,2-h]quinazolines and/or 5,6-dihydro derivatives thereof, a method for the production thereof and doped organic semiconductor material containing these | NOVALED AG (DE) | 2009-01-21 | — | — | CN | disclosed |
| CN-101277700-A | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-01 | — | — | CN | disclosed |
| CN-100393706-C | Substituted dihydrochinazolines having antiviral properties | BAYER HEALTHCARE AG (DE) | 2008-06-11 | — | — | CN | disclosed |
| CN-101151051-A | Analgesic combination of sodium channel blockers with opioid antagonists | WEX PHARMACEUTICALS INC (CA) | 2008-03-26 | — | — | CN | disclosed |
| US-20070275911-A1 | Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2007-11-29 | — | — | US | disclosed |
| CN-1934113-A | Compositions useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-03-21 | — | — | CN | disclosed |
| CN-1784390-A | Substituted dihydrochinazolines having antiviral properties | BAYER HEALTHCARE AG (DE) | 2006-06-07 | — | — | CN | disclosed |
| WO-2005034856-A2 | TARGETED DRUG-FORMALDEHYDE CONJUGATES AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2005-04-21 | — | — | WO | disclosed |
| CN-1044245-C | Tricyclic Dicarbonyl derivatives | HAFFMANN LA ROCHE AG F (DE) | 1999-07-21 | — | — | CN | disclosed |
| CN-1149295-A | Tricyclic Dicarbonyl derivatives | HOFFMANN LA ROCHE (CH) | 1997-05-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275911-A1 | Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same | HCAR1, DHFR, FOLR1 | EGFR 97/4885PIK3CD 3828/4885PIK3CA 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.